Skip to main content
LLY
NYSE Life Sciences

Lilly's Foundayo Cuts Cardiovascular Death by 53% in Landmark Diabetes Trial

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1,162.578
Mkt Cap
$1.089T
52W Low
$725.31
52W High
$1,292.65
52W Position info
60% above low
Off High info
10% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

LLY sits 60% above its 52-week low of $725.31.

Summary

Lilly's oral GLP-1 Foundayo (orforglipron) delivered striking cardiovascular outcomes in the ACHIEVE-4 trial, its largest and longest type 2 diabetes study. The drug showed a 53% lower risk of cardiovascular death and 57% lower all-cause death versus insulin glargine, along with reduced MACE-4 by 16%, MACE-3 by 23%, and improved cardiometabolic health. It also slowed kidney decline with 2.8 mL/min/1.73 m² smaller eGFR reduction and 27.1% greater albuminuria reduction. These results position Foundayo as a potential first-line oral option with hard-outcome benefits, not just glucose control. This follows the FDA approval of Foundayo for obesity and the recent Mounjaro cardiovascular indication, reinforcing Lilly's dominance in cardiometabolic disease. The data could accelerate adoption and support premium pricing, with regulatory submissions for cardiovascular claims likely next. Eli Lilly says Foundayo helped patients lose weight in a Phase 3 trial.

Updated with a Benzinga report · What changed

Updates

  1. · Benzinga — ACHIEVE-4 showed Foundayo reduced MACE-4 by 16%, MACE-3 by 23%, and slowed kidney decline with 2.8 mL/min/1.73 m² smaller eGFR reduction and 27.1% greater albuminuria reduction.

At the time of this announcement, LLY was trading at $1,162.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $725.31 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 18, 2026, 3:04 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,381.18
Real-time Price: $1,380.22 info
Change: -$0.960 (-0.07%) info
Market Cap: $1.301T info
LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,380.22 info
Change: -$36.00 (-3%) info
Market Cap: $1.301T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,380.22 info
Change: -$75.14 (-5%) info
Market Cap: $1.301T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,380.22 info
Change: -$72.47 (-5%) info
Market Cap: $1.301T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,380.22 info
Change: -$67.63 (-5%) info
Market Cap: $1.301T info